Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
about
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection modelsPharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model.Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model.Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system
P2860
Q33981554-66AAC803-B52C-4D0C-979E-7CB2E20E27B4Q34104410-B04493E6-0B70-4CF1-9B50-1045D4CEF21AQ34108149-5DB45FA1-1D18-46AF-84DC-56A251E9607EQ34108406-9112E447-451B-4BBF-AA88-C27EEC3843ABQ34230600-3EB36A84-0BB6-409F-A256-183948A2821CQ35685485-1FC0B3F1-F15F-4851-AE89-E5EFD4AF1C2FQ36933417-9F3FEDAA-439E-45EA-B854-35A5FF40523CQ39477806-90D46D7A-DE51-47E0-BEB1-21424A1B8332Q39478611-BA7C3F9D-6EBC-4F98-96A2-22C093B29668Q39650985-C0C2D216-225E-4461-9B3A-C91E03B68842Q39731788-2AB4476D-F020-4094-A064-63F3B25F2B99Q39746333-29E7A101-D8B9-470D-9492-1C96FFD07656Q41003618-D12020F3-F8DE-4571-A622-9AE247A62BE0
P2860
Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Pharmacodynamics of trovafloxa ...... n vitro pharmacokinetic model.
@ast
Pharmacodynamics of trovafloxa ...... n vitro pharmacokinetic model.
@en
type
label
Pharmacodynamics of trovafloxa ...... n vitro pharmacokinetic model.
@ast
Pharmacodynamics of trovafloxa ...... n vitro pharmacokinetic model.
@en
prefLabel
Pharmacodynamics of trovafloxa ...... n vitro pharmacokinetic model.
@ast
Pharmacodynamics of trovafloxa ...... n vitro pharmacokinetic model.
@en
P2860
P1476
Pharmacodynamics of trovafloxa ...... n vitro pharmacokinetic model.
@en
P2093
C C Sanders
P D Lister
P2860
P304
P407
P577
1999-05-01T00:00:00Z